Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Odetiglucan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Odetiglucan: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vardenafil(Respira Therapeutics, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Vardenafil(Respira Therapeutics, Inc.): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Bryostatin 1/Valproic Acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Bryostatin 1/Valproic Acid: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Pemafibrate/Tofogliflozin Hydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Pemafibrate/Tofogliflozin Hydrate: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Calcipotriol/Nicotinamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Calcipotriol/Nicotinamide: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Rigosertib Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
Rigosertib Sodium: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
DPP4 Biologics Sequence Review Report 2026: Dipeptidyl peptidase 4 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DPP4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
DLL1 Biologics Sequence Review Report 2026: Delta-like protein 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DLL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
DDR2 Biologics Sequence Review Report 2026: Discoidin domain-containing receptor 2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DDR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
DDR1 Biologics Sequence Review Report 2026: Epithelial discoidin domain-containing receptor 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DDR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CXCL12 Biologics Sequence Review Report 2026: Stromal cell-derived factor 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CXCL12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CX3CL1 Biologics Sequence Review Report 2026: Fractalkine Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CX3CL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.